Similar articles

Abstract: 5-Hydroxytryptamine (5-HT) type 3 receptor (5-HT₃R) is the only type of ligand-gated ion channel in the 5-HT receptor family. Through the high permeability of Na⁺, K⁺, and Ca²⁺ and activation of subsequent voltage-gated calcium channels (VGCCs), 5-HT₃R induces a rapid increase of neuronal excitability or the release of neurotransmitters from axon terminals in the central nervous system (CNS). 5-HT₃Rs are widely expressed in the medial prefrontal cortex (mPFC), amygdala (AMYG), hippocampus (HIP), periaqueductal gray (PAG), and other brain regions closely associated with anxiety reactions. They have a bidirectional regulatory effect on anxiety reactions by acting on different types of cells in different brain regions. 5-HT₃Rs mediate the activation of the cholecystokinin (CCK) system in the AMYG, and the γ‍-aminobutyric acid (GABA) “disinhibition” mechanism in the prelimbic area of the mPFC promotes anxiety by the activation of GABAergic intermediate inhibitory neurons (IINs). In contrast, a 5-HT₃R-induced GABA “disinhibition” mechanism in the infralimbic area of the mPFC and the ventral HIP produces anxiolytic effects. 5-HT₂R-mediated regulation of anxiety reactions are also activated by 5-HT₃R-activated 5-HT release in the HIP and PAG. This provides a theoretical basis for the treatment of anxiety disorders or the production of anxiolytic drugs by targeting 5-HT₃Rs. However, given the circuit specific modulation of 5-HT₃Rs on emotion, systemic use of 5-HT₃R agonism or antagonism alone seems unlikely to remedy anxiety, which deeply hinders the current clinical application of 5-HT₃R drugs. Therefore, the exploitation of circuit targeting methods or a combined drug strategy might be a useful developmental approach in the future.

5-羟色胺3受体对焦虑反应的调节作用

[1]AbelaAR, BrowneCJ, SarginD, et al., 2020. Median raphe serotonin neurons promote anxiety-like behavior via inputs to the dorsal hippocampus. Neuropharmacology, 168:107985.

[2]al KuryLT, MahgoubM, HowarthFC, et al., 2018. Natural negative allosteric modulators of 5-HT₃ receptors. Molecules, 23(12):3186.

[3]AlvesSH, PinheiroG, MottaV, et al., 2004. Anxiogenic effects in the rat elevated plus-maze of 5-HT_2C agonists into ventral but not dorsal hippocampus. Behav Pharmacol, 15(1):37-43.

[4]AndradeTGCS, MacedoCEA, ZangrossiH, et al., 2004. Anxiolytic-like effects of median raphe nucleus lesion in the elevated T-maze. Behav Brain Res, 153(1):55-60.

[5]ArtaizI, RomeroG, ZazpeA, et al., 1995. The pharmacology of VA₂₁B₇: an atypical 5-HT₃ receptor antagonist with anxiolytic-like properties in animal models. Psychopharmacology, 117(2):137-148.

[6]AskariN, MoinM, SanatiM, et al., 2012. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs, 26(10):883-892.

[7]BabaevO, Piletti ChatainC, Krueger-BurgD, 2018. Inhibition in the amygdala anxiety circuitry. Exp Mol Med, 50(4):1-16.

[8]BannermanDM, MatthewsP, DeaconRM, et al., 2004. Medial septal lesions mimic effects of both selective dorsal and ventral hippocampal lesions. Behav Neurosci, 118(5):1033-1041.

[9]BarnesJM, BarnesNM, CostallB, et al., 1990. Identification and distribution of 5-HT₃ recognition sites within the human brainstem. Neurosci Lett, 111(1-2):80-86.

[10]BarnesNM, HalesTG, LummisSCR, et al., 2009. The 5-HT₃ receptor ‍– the relationship between structure and function. Neuropharmacology, 56(1):273-284.

[11]BasakS, GicheruY, SamantaA, et al., 2018. Cryo-EM structure of 5-HT_3A receptor in its resting conformation. Nat Commun, 9:514.

[12]BhatnagarS, NowakN, BabichL, et al., 2004. Deletion of the 5-HT₃ receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests. Behav Brain Res, 153(2):527-535.

[13]BhattS, MaheshR, DevadossT, et al., 2013. Anxiolytic-like effect of (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in experimental mouse models of anxiety. Indian J Pharmacol, 45(3):248-251.

[14]BhattS, MaheshR, JindalA, et al., 2017a. Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT₃ receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats. J Basic Clin Physiol Pharmacol, 28(2):93-100.

[15]BhattS, MaheshR, DevadossT, et al., 2017b. Neuropharmacological evaluation of a novel 5-HT₃ receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) on lipopolysaccharide-induced anxiety models in mice. J Basic Clin Physiol Pharmacol, 28(2):101-106.

[16]BhattS, DevadossT, ManjulaSN, et al., 2021. 5-HT₃ receptor antagonism: a potential therapeutic approach for the treatment of depression and other disorders. Curr Neuropharmacol, 19(9):1545-1559.

[17]BiWK, LuanSS, WangJ, et al., 2020. FSH signaling is involved in affective disorders. Biochem Biophys Res Commun, 525(4):915-920.

[18]BirbaumerN, GroddW, DiedrichO, et al., 1998. fMRI reveals amygdala activation to human faces in social phobics. NeuroReport, 9(6):1223-1226.

[19]BremnerJD, RandallP, ScottTM, et al., 1995. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry, 152(7):973-981.

[20]BremnerJD, HoffmanM, AfzalN, et al., 2021. The environment contributes more than genetics to smaller hippocampal volume in Posttraumatic Stress Disorder (PTSD). J Psychiatr Res, 137:579-588.

[21]CampbellAD, WomerDE, SimonJR, 1995. The 5-HT₃ receptor agonist 1-‍(m-chlorophenyl)‍-biguanide interacts with the dopamine transporter in rat brain synaptosomes. Eur J Pharmacol: Mol Pharmacol, 290(2):157-162.

[22]CelliJ, RappoldG, NieslerB, 2017. The human serotonin type 3 receptor gene (HTR3A-E) allelic variant database. Hum Mutat, 38(2):137-147.

[23]ChallisC, BeckSG, BertonO, 2014. Optogenetic modulation of descending prefrontocortical inputs to the dorsal raphe bidirectionally bias socioaffective choices after social defeat. Front Behav Neurosci, 8:43.

[24]ChoiIS, ChoJH, KimJT, et al., 2007. Serotoninergic modulation of GABAergic synaptic transmission in developing rat CA3 pyramidal neurons. J Neurochem, 103(6):‍2342-2353.

[25]Cortes-AltamiranoJL, Olmos-HernandezA, JaimeHB, et al., 2018. Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 receptors and their role in the modulation of pain response in the central nervous system. Curr Neuropharmacol, 16(2):210-221.

[26]CostallB, KellyME, NaylorRJ, et al., 1989. Neuroanatomical sites of action of 5-HT₃ receptor agonist and antagonists for alteration of aversive behaviour in the mouse. Br J Pharmacol, 96(2):325-332.

[27]CrocqMA, 2015. A history of anxiety: from hippocrates to DSM. Dialogues Clin Neurosci, 17(3):319-325.

[28]CutlerMG, 1991. An ethological study of the effects of buspirone and the 5-HT₃ receptor antagonist, BRL 43694 (granisetron) on behaviour during social interactions in female and male mice. Neuropharmacology, 30(4):299-306.

[29]de la MoraMP, Hernández-GómezAM, Arizmendi-GarcíaY, et al., 2007. Role of the amygdaloid cholecystokinin (CCK)/gastrin-2 receptors and terminal networks in the modulation of anxiety in the rat. Effects of CCK-4 and CCK-8S on anxiety-like behaviour and [³H]GABA release. Eur J Neurosci, 26(12):3614-3630.

[30]del BocaC, LutzPE, le MerrerJ, et al., 2012. Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice. Neuroscience, 218:185-195.

[31]el NebrisiE, PrytkovaT, LorkeDE, et al., 2020. Capsaicin is a negative allosteric modulator of the 5-HT₃ receptor. Front Pharmacol, 11:1274.

[32]EnginE, TreitD, 2007. The role of hippocampus in anxiety: intracerebral infusion studies. Behav Pharmacol, 18(5-6):365-374.

[33]FawleyJA, DoyleMW, AndresenMC, 2019. 5-HT₃R-sourced calcium enhances glutamate release from a distinct vesicle pool. Brain Res, 1721:146346.

[34]GasiorekA, TrattnigSM, AhringPK, et al., 2016. Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT₃ receptors. Biochem Pharmacol, 110-111:92-108.

[35]GiacobbeP, FlintA, 2018. Diagnosis and management of anxiety disorders. Continuum (Minneap Minn), 24(3):893-919.

[36]GibbsE, ChakrapaniS, 2021. Structure, function and physiology of 5-hydroxytryptamine receptors subtype 3. In: Harris JR, Marles-Wright J (Eds.), Macromolecular Protein Complexes III: Structure and Function. Springer, Cham, p.373-408.

[37]GiordanoJ, GerstmannH, 2004. Patterns of serotonin- and 2-methylserotonin-induced pain may reflect 5-HT₃ receptor sensitization. Eur J Pharmacol, 483(2-3):267-269.

[38]GriffithsJL, LovickTA, 2002. Co-localization of 5-HT_2A-receptor- and GABA-immunoreactivity in neurones in the periaqueductal grey matter of the rat. Neurosci Lett, 326(3):151-154.

[39]GuiZH, ZhangQJ, LiuJ, et al., 2010. In vivo modulation of the firing activity of putative slow- and fast-spiking interneurons in the medial prefrontal cortex by 5-HT₃ receptors in 6-hydroxydopamine-induced Parkinsonian rats. Neuroscience, 169(3):1315-1325.

[40]GuptaD, ThangarajD, RadhakrishnanM, 2016. A novel 5HT₃ antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: modulation of serotonergic system. Behav Brain Res, 297:41-50.

[41]HarmerCJ, ReidCB, RayMK, et al., 2006. 5HT₃ antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology, 186:18-24.

[42]HarrellAV, AllanAM, 2003. Improvements in hippocampal-dependent learning and decremental attention in 5-HT₃ receptor overexpressing mice. Learn Mem, 10(5):410-419.

[43]HausU, VargaB, StratzT, et al., 2000. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol, 29(113):55-58.

[44]HenslerJG, HodgeCW, OverstreetDH, 2004. Reduced 5-HT₃ receptor binding and lower baseline plus maze anxiety in the alcohol-preferring inbred fawn-hooded rat. Pharmacol Biochem Behav, 77(2):281-289.

[45]HewlettWA, SchmidSP, SalomonRM, 2003. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry, 64(9):1025-1030.

[46]HigginsGA, JonesBJ, OakleyNR, et al., 1991. Evidence that the amygdala is involved in the disinhibitory effects of 5-HT₃ receptor antagonists. Psychopharmacology, 104(4):545-551.

[47]HolmL, LiangW, ThorsellA, et al., 2014. Acute effects on brain cholecystokinin-like concentration and anxiety-like behaviour in the female rat upon a single injection of 17β‍-estradiol. Pharmacol Biochem Behav, 122:222-227.

[48]HutchisonSM, MâsseLC, PawluskiJL, et al., 2021. Perinatal selective serotonin reuptake inhibitor (SSRI) and other antidepressant exposure effects on anxiety and depressive behaviors in offspring: a review of findings in humans and rodent models. Reprod Toxicol, 99:80-95.

[49]IrvingH, TurekI, KettleC, et al., 2021. Tapping into 5-HT₃ receptors to modify metabolic and immune responses. Int J Mol Sci, 22(21):11910.

[50]JuzaR, VlcekP, MezeiovaE, et al., 2020. Recent advances with 5-HT₃ modulators for neuropsychiatric and gastrointestinal disorders. Med Res Rev, 40(5):1593-1678.

[51]KilpatrickGJ, JonesBJ, TyersMB, 1987. Identification and distribution of 5-HT₃ receptors in rat brain using radioligand binding. Nature, 330(6150):746-748.

[52]KilpatrickGJ, ButlerA, BurridgeJ, et al., 1990. 1-‍(m-Chlorophenyl)‍-biguanide, a potent high affinity 5-HT₃ receptor agonist. Eur J Pharmacol, 182(1):193-197.

[53]KochSBJ, van ZuidenM, NawijnL, et al., 2017. Decreased uncinate fasciculus tract integrity in male and female patients with PTSD: a diffusion tensor imaging study. J Psychiatry Neurosci, 42(5):331-342.

[54]KoyamaY, KondoM, ShimadaS, 2017. Building a 5-HT₃A receptor expression map in the mouse brain. Sci Rep, 7:42884.

[55]KurheY, MaheshR, DevadossT, 2015. QCM-4, a 5-HT₃ receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice. Biochem Biophys Res Commun, 456(1):74-79.

[56]KurheY, MaheshR, DevadossT, 2017. Novel 5-HT₃ receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice. Psychopharmacology, 234(7):1165-1179.

[57]LakhtakiaT, TorousJ, 2022. Current directions in digital interventions for mood and anxiety disorders. Curr Opin Psychiatry, 35(2):130-135.

[58]LecrubierY, PuechAJ, AzconaA, et al., 1993. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology, 112:129-133.

[59]LiHH, LiuYT, GaoXQ, et al., 2019. Neuroplastin 65 modulates anxiety- and depression-like behavior likely through adult hippocampal neurogenesis and central 5-HT activity. FEBS J, 286(17):3401-3415.

[60]LopesLT, Canto-de-SouzaL, Baptista-de-SouzaD, et al., 2022. The interplay between 5-HT_2C and 5-HT_3A receptors in the dorsal periaqueductal gray mediates anxiety-like behavior in mice. Behav Brain Res, 417:113588.

[61]LummisSCR, 2012. 5-HT₃ receptors. J Biol Chem, 287(48):40239-40245.

[62]MachuTK, 2011. Therapeutics of 5-HT₃ receptor antagonists: current uses and future directions. Pharmacol Ther, 130(3):338-347.

[63]MaksayG, BíróT, BugovicsG, 2005. Allosteric modulation of 5-HT₃ serotonin receptors. Eur J Pharmacol, 514(1):17-24.

[64]MarcinkiewczCA, MazzoneCM, D'AgostinoG, et al., 2016. Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala. Nature, 537(7618):97-101.

[65]MartinKF, HannonS, PhillipsI, et al., 1992. Opposing roles for 5-HT_1B and 5-HT₃ receptors in the control of 5-HT release in rat hippocampus in vivo. Br J Pharmacol, 106(1):139-142.

[66]MascagniF, McDonaldAJ, 2007. A novel subpopulation of 5-HT type 3A receptor subunit immunoreactive interneurons in the rat basolateral amygdala. Neuroscience, 144(3):1015-1024.

[67]McCannUD, MorganCM, GeraciM, et al., 1997. Effects of the 5-HT₃ antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology, 17(6):360-369.

[68]MendelsonSD, McEwenBS, 1991. Autoradiographic analyses of the effects of restraint-induced stress on 5-HT_1A, 5-HT_1C and 5-HT₂ receptors in the dorsal hippocampus of male and female rats. Neuroendocrinology, 54(5):454-461.

[69]MillanMJ, 2022. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. Ther Adv Psychopharmacol, 12:20451253221105128.

[70]MotzkinJC, PhilippiCL, WolfRC, et al., 2015. Ventromedial prefrontal cortex is critical for the regulation of amygdala activity in humans. Biol Psychiatry, 77(3):276-284.

[71]MurphySE, CapitãoLP, GilesSLC, et al., 2021. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. Lancet Psychiatry, 8(9):824-835.

[72]NowickiM, TranS, MuraleetharanA, et al., 2014. Serotonin antagonists induce anxiolytic and anxiogenic-like behavior in zebrafish in a receptor-subtype dependent manner. Pharmacol Biochem Behav, 126:170-180.

[73]PallantiS, BernardiS, AntoniniS, et al., 2009. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs, 23(12):1047-1055.

[74]ParkJ, MoghaddamB, 2017. Impact of anxiety on prefrontal cortex encoding of cognitive flexibility. Neuroscience, 345:193-202.

[75]RigaMS, SánchezC, CeladaP, et al., 2016. Involvement of 5-HT₃ receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology, 108:73-81.

[76]RoganMT, StäubliUV, LedouxJE, 1997. Fear conditioning induces associative long-term potentiation in the amygdala. Nature, 390(6660):604-607.

[77]SahP, 2017. Fear, anxiety, and the amygdala. Neuron, 96(1):1-2.

[78]SerataD, KotzalidisGD, RapinesiC, et al., 2015. Are 5-HT₃ antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum Psychopharmacol, 30(2):70-84.

[79]SharafkhahM, AlamdarMA, MassoudifarA, et al., 2019. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. Int Clin Psychopharmacol, 34(5):222-233.

[80]SharpT, BarnesNM, 2020. Central 5-HT receptors and their function; present and future. Neuropharmacology, 177:108155.

[81]ŚlifirskiG, KrólM, TurłoJ, 2021. 5-HT receptors and the development of new antidepressants. Int J Mol Sci, 22(16):9015.

[82]SmithWT, LondborgPD, BlomgrenSL, et al., 1999. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol, 19(2):125-131.

[83]SoltK, RueschD, FormanSA, et al., 2007. Differential effects of serotonin and dopamine on human 5-HT_3A receptor kinetics: interpretation within an allosteric kinetic model. J Neurosci, 27(48):13151-13160.

[84]SoltaniF, SayyahM, FeizyF, et al., 2010. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol, 25(6):509-513.

[85]StefańskiR, PałejkoW, BidzinskiA, et al., 1993. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of the 5-HT₃ receptor antagonists. Neuropharmacology, 32(10):‍987-993.

[86]SzeszkoPR, RobinsonD, AlvirJMJ, et al., 1999. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch Gen Psychiatry, 56(10):913-919.

[87]TaylorNE, PeiJZ, ZhangJ, et al., 2019. The role of glutamatergic and dopaminergic neurons in the periaqueductal gray/dorsal raphe: separating analgesia and anxiety. eNeuro, 6(1):ENEURO.0018-18.2019.

[88]TogaoO, YoshiuraT, NakaoT, et al., 2010. Regional gray and white matter volume abnormalities in obsessive-compulsive disorder: a voxel-based morphometry study. Psychiatry Res Neuroimaging, 184(1):29-37.

[89]TovoteP, FadokJP, LüthiA, 2015. Neuronal circuits for fear and anxiety. Nat Rev Neurosci, 16(6):317-331.

[90]TovoteP, EspositoMS, BottaP, et al., 2016. Midbrain circuits for defensive behaviour. Nature, 534(7606):206-212.

[91]TseilikmanV, AkulovA, ShevelevO, et al., 2022. Paradoxical anxiety level reduction in animal chronic stress: a unique role of hippocampus neurobiology. Int J Mol Sci, 23(16):9151.

[92]TurnerTJ, MoklerDJ, LuebkeJI, 2004. Calcium influx through presynaptic 5-HT₃ receptors facilitates GABA release in the hippocampus: in vitro slice and synaptosome studies. Neuroscience, 129(3):703-718.

[93]Urzedo-RodriguesLS, FerreiraHS, SantanaRC, et al., 2014. Blockade of 5-HT₃ receptors in the septal area increases Fos expression in selected brain areas. Auton Neurosci, 181:55-68.

[94]Uvnäs-MobergK, HillegaartV, AlsterP, et al., 1996. Effects of 5-HT agonists, selective for different receptor subtypes, on oxytocin, CCK, gastrin and somatostatin plasma levels in the rat. Neuropharmacology, 35(11):1635-1640.

[95]Vilela-CostaHH, MaraschinJC, CasarottoPC, et al., 2021. Role of 5-HT_1A and 5-HT_2C receptors of the dorsal periaqueductal gray in the anxiety- and panic-modulating effects of antidepressants in rats. Behav Brain Res, 404:113159.

[96]VuV, Conant-NorvilleD, 2021. Anxiety: recognition and treatment options. Psychiatr Clin North Am, 44(3):373-380.

[97]YakelJL, JacksonMB, 1988. 5-HT₃ receptors mediate rapid responses in cultured hippocampus and a clonal cell line. Neuron, 1(7):615-621.

[98]YakelJL, ShaoXM, JacksonMB, 1990. The selectivity of the channel coupled to the 5-HT₃ receptor. Brain Res, 533(1):46-52.

[99]ZhaoHY, LinY, ChenSR, et al., 2018. 5-HT₃ receptors: a potential therapeutic target for epilepsy. Curr Neuropharmacol, 16(1):29-36.

[100]ZwanzgerP, DomschkeK, BradwejnJ, 2012. Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety, 29(9):762-774.